Page last updated: 2024-12-09
fm19g11
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
FM19G11: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 1730746 |
CHEMBL ID | 1542356 |
CHEBI ID | 121799 |
SCHEMBL ID | 13709113 |
MeSH ID | M0554268 |
Synonyms (38)
Synonym |
---|
OPREA1_340477 |
smr000164156 |
MLS000545862 , |
2-(4-methylphenyl)-2-oxoethyl 3-{[(2,4-dinitrophenyl)carbonyl]amino}benzoate |
STK268528 |
AK-918/11884136 |
2-(4-methylphenyl)-2-oxoethyl 3-({2,4-dinitrobenzoyl}amino)benzoate |
CHEBI:121799 |
AKOS003241071 |
[2-(4-methylphenyl)-2-oxoethyl] 3-[(2,4-dinitrobenzoyl)amino]benzoate |
HMS2416A18 |
[2-oxo-2-(p-tolyl)ethyl] 3-[(2,4-dinitrobenzoyl)amino]benzoate |
329932-55-0 |
fm19g11 |
[2-(4-methylphenyl)-2-oxidanylidene-ethyl] 3-[(2,4-dinitrophenyl)carbonylamino]benzoate |
cid_1730746 |
3-[(2,4-dinitrobenzoyl)amino]benzoic acid [2-keto-2-(p-tolyl)ethyl] ester |
3-[[(2,4-dinitrophenyl)-oxomethyl]amino]benzoic acid [2-(4-methylphenyl)-2-oxoethyl] ester |
bdbm76423 |
SCHEMBL13709113 |
CHEMBL1542356 |
Q27210371 |
DTXSID80365023 |
fm19g11, >=98% (hplc) |
CS-0008218 |
HY-15672 |
J-018963 |
2-oxo-2-(p-tolyl)ethyl 3-(2,4-dinitrobenzamido)benzoate |
2-oxo-2-p-tolylethyl 3-(2,4-dinitrobenzamido)benzoate |
EX-A3475 |
fm 19g11 |
hif-1alpha/2alpha inhibitor |
MS-28522 |
AC-36404 |
BF168364 |
hif-1alpha/2alpha inhibitor iv |
hif inhibitor iv |
AKOS040755424 |
Research Excerpts
Effects
Excerpt | Reference | Relevance |
---|---|---|
"FM19G11, which has been shown to enhance self-renewal properties, rescues cell viability at 6 days." | ( Methacrylate-endcapped caprolactone and FM19G11 provide a proper niche for spinal cord-derived neural cells. Alastrue-Agudo, A; Erceg, S; Escobar-Ivirico, JL; García-Cruz, DM; Monleón, M; Moreno-Manzano, V; Rodriguez-Jimenez, FJ; Valdes-Sánchez, T, 2015) | 1.41 |
Compound-Compound Interactions
Excerpt | Reference | Relevance |
---|---|---|
" We hypothesized that targeting HIF-1α alone or in combination with other metabolic regulators could promote the metabolic maturation of hiPSC-CMs." | ( Targeting HIF-1α in combination with PPARα activation and postnatal factors promotes the metabolic maturation of human induced pluripotent stem cell-derived cardiomyocytes. Brown, LA; Duan, M; Gentillon, C; Gibson, GC; Jha, R; Li, D; Preininger, MK; Qu, CK; Rampoldi, A; Saraf, A; Xu, C; Yu, WM, 2019) | 0.51 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (1)
Class | Description |
---|---|
benzamides | |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein Targets (24)
Potency Measurements
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 3.1623 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 12.5893 | 0.6310 | 35.7641 | 100.0000 | AID504339 |
Chain A, Ferritin light chain | Equus caballus (horse) | Potency | 1.7783 | 5.6234 | 17.2929 | 31.6228 | AID485281 |
Chain A, Cruzipain | Trypanosoma cruzi | Potency | 39.8107 | 0.0020 | 14.6779 | 39.8107 | AID1476 |
Luciferase | Photinus pyralis (common eastern firefly) | Potency | 0.1069 | 0.0072 | 15.7588 | 89.3584 | AID588342 |
glp-1 receptor, partial | Homo sapiens (human) | Potency | 31.8326 | 0.0184 | 6.8060 | 14.1254 | AID624172; AID624417 |
thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 14.1254 | 0.1000 | 20.8793 | 79.4328 | AID588453 |
BRCA1 | Homo sapiens (human) | Potency | 35.4813 | 0.8913 | 7.7225 | 25.1189 | AID624202 |
ATAD5 protein, partial | Homo sapiens (human) | Potency | 3.1278 | 0.0041 | 10.8903 | 31.5287 | AID504466; AID504467 |
TDP1 protein | Homo sapiens (human) | Potency | 20.5962 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Smad3 | Homo sapiens (human) | Potency | 10.0000 | 0.0052 | 7.8098 | 29.0929 | AID588855 |
NPC intracellular cholesterol transporter 1 precursor | Homo sapiens (human) | Potency | 0.3981 | 0.0126 | 2.4518 | 25.0177 | AID485313 |
parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 22.3872 | 3.5481 | 19.5427 | 44.6684 | AID743266 |
huntingtin isoform 2 | Homo sapiens (human) | Potency | 5.6234 | 0.0006 | 18.4198 | 1,122.0200 | AID1688 |
ras-related protein Rab-9A | Homo sapiens (human) | Potency | 1.4125 | 0.0002 | 2.6215 | 31.4954 | AID485297 |
lethal(3)malignant brain tumor-like protein 1 isoform I | Homo sapiens (human) | Potency | 44.6684 | 0.0752 | 15.2253 | 39.8107 | AID485360 |
geminin | Homo sapiens (human) | Potency | 32.6427 | 0.0046 | 11.3741 | 33.4983 | AID624296 |
survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 12.5893 | 0.1259 | 12.2344 | 35.4813 | AID1458 |
muscleblind-like protein 1 isoform 1 | Homo sapiens (human) | Potency | 5.6234 | 0.0041 | 9.9625 | 28.1838 | AID2675 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Inhibition Measurements
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
SUMO-1-specific protease | Homo sapiens (human) | IC50 (µMol) | 4.8900 | 0.8050 | 19.3461 | 87.7000 | AID488921 |
SUMO1/sentrin specific peptidase 7 | Homo sapiens (human) | IC50 (µMol) | 5.9700 | 1.6400 | 7.2648 | 23.9000 | AID488904 |
caspase-3 isoform a preproprotein | Homo sapiens (human) | IC50 (µMol) | 22.2000 | 0.0256 | 20.3235 | 74.3000 | AID488901 |
sentrin-specific protease 8 | Homo sapiens (human) | IC50 (µMol) | 100.0000 | 0.0408 | 18.9292 | 94.8000 | AID488903 |
Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | IC50 (µMol) | 2.6000 | 0.0007 | 2.4652 | 9.2100 | AID1597990 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Biological Processes (84)
Molecular Functions (23)
Ceullar Components (12)
Process | via Protein(s) | Taxonomy |
---|---|---|
nucleus | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
nucleoplasm | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
cytoplasm | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
cytosol | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
nuclear body | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
nuclear speck | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
motile cilium | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
axon cytoplasm | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
chromatin | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
euchromatin | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
protein-containing complex | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
RNA polymerase II transcription regulator complex | Hypoxia-inducible factor 1-alpha | Homo sapiens (human) |
[Information is prepared from geneontology information from the June-17-2024 release] |
Bioassays (14)
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1597990 | Inhibition of HIF-1alpha in human HeLa cells after 6 hrs by luciferase reporter gene assay | 2019 | Journal of medicinal chemistry, 06-27, Volume: 62, Issue:12 | Small-Molecule Modulators of the Hypoxia-Inducible Factor Pathway: Development and Therapeutic Applications. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Research
Studies (18)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (5.56) | 29.6817 |
2010's | 16 (88.89) | 24.3611 |
2020's | 1 (5.56) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 19.39
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (19.39) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 1 (5.56%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 17 (94.44%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |